Saša Dimitrijević
About
Saša Dimitrijević is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology and Molecular Biology.
According to data from OpenAlex, Saša Dimitrijević has authored 49 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 16 papers in Gastroenterology and 12 papers in Molecular Biology. Recurrent topics in Saša Dimitrijević's work include Gastrointestinal Tumor Research and Treatment (16 papers), Chronic Myeloid Leukemia Treatments (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Saša Dimitrijević is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (16 papers), Chronic Myeloid Leukemia Treatments (10 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Saša Dimitrijević collaborates with scholars based in United States, Switzerland and United Kingdom. Saša Dimitrijević's co-authors include Sandra Silberman, George D. Demetri, Heikki Joensuu, Peter Roberts, Brian Druker, Christopher D.�M. Fletcher, Ian Judson, Michael C. Heinrich, Raf Sciot and Renaud Capdeville and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
In The Last Decade
Saša Dimitrijević
47 papers receiving 8.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Saša Dimitrijević United States | 24 | 4.8k | 4.3k | 2.1k | 1.7k | 1.5k | 49 | 8.4k | ||
| Sandra Silberman United States | 15 | 4.0k 0.8× | 3.5k 0.8× | 1.8k 0.8× | 1.8k 1.0× | 1.0k 0.7× | 38 | 6.8k | ||
| Jonathan A. Fletcher United States | 57 | 5.6k 1.1× | 2.5k 0.6× | 1.8k 0.8× | 1.7k 1.0× | 2.4k 1.6× | 129 | 9.5k | ||
| Maria Dêbiec‐Rychter Belgium | 59 | 7.5k 1.5× | 4.2k 1.0× | 2.5k 1.2× | 2.7k 1.5× | 2.4k 1.6× | 318 | 12.3k | ||
| A. van Oosterom Belgium | 34 | 4.2k 0.9× | 3.1k 0.7× | 1.7k 0.8× | 1.8k 1.1× | 861 0.6× | 88 | 6.7k | ||
| Jonathan C. Trent United States | 48 | 5.1k 1.1× | 3.5k 0.8× | 2.2k 1.1× | 2.5k 1.4× | 1.3k 0.9× | 283 | 8.2k | ||
| Annick D. Van den Abbeele United States | 43 | 4.4k 0.9× | 2.3k 0.5× | 1.8k 0.8× | 3.3k 1.9× | 1.5k 1.0× | 146 | 8.8k | ||
| Laura McGreevey United States | 14 | 3.3k 0.7× | 3.5k 0.8× | 1.8k 0.8× | 696 0.4× | 723 0.5× | 16 | 5.4k | ||
| Ajia Town United States | 13 | 2.9k 0.6× | 2.9k 0.7× | 1.4k 0.7× | 1.1k 0.7× | 1.2k 0.8× | 17 | 5.3k | ||
| Maarit Sarlomo‐Rikala Finland | 38 | 5.8k 1.2× | 6.1k 1.4× | 4.1k 1.9× | 1.4k 0.8× | 826 0.6× | 57 | 9.3k | ||
| Axel Le Cesne France | 56 | 7.9k 1.6× | 2.6k 0.6× | 2.1k 1.0× | 4.3k 2.5× | 1.1k 0.7× | 270 | 10.6k |
Countries citing papers authored by Saša Dimitrijević
Since
Specialization
Citations
This map shows the geographic impact of Saša Dimitrijević's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saša Dimitrijević with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saša Dimitrijević more than expected).
Fields of papers citing papers by Saša Dimitrijević
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Saša Dimitrijević. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saša Dimitrijević. The network helps show where Saša Dimitrijević may publish in the future.
Co-authorship network of co-authors of Saša Dimitrijević
This figure shows the co-authorship network connecting the top 25 collaborators of Saša Dimitrijević. A scholar is included among the top collaborators of Saša Dimitrijević based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saša Dimitrijević. Saša Dimitrijević is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Reiter, Andreas, Jason Gotlib, Iván Álvarez‐Twöse, et al.. (2025). Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control study. Leukemia Research. 157. 107919–107919.
2.
Pyatilova, Polina, Jonathan A. Bernstein, Mario Sánchez Borges, et al.. (2023). The diagnostic workup for systemic mastocytosis differs from consensus recommendations: Results of a worldwide survey. World Allergy Organization Journal. 16(11). 100838–100838.
3.
Babić, Rade, Saša Dimitrijević, & Ivana Burazor. (2023). Association of extent and severity of coronary atheromatosis with clinically undetected depression. European Heart Journal. 44(Supplement_2).
4.
Radia, Deepti, Jason Gotlib, Mark W. Drummond, et al.. (2022). Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study. Blood. 140(Supplement 1). 1509–1511.
5.
DeAngelo, Daniel J., Deepti Radia, Tracy I. George, et al.. (2022). An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety. Blood. 140(Supplement 1). 3932–3934.
6.
Mehren, Margaret von, Michael C. Heinrich, Hongliang Shi, et al.. (2021). Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. BMC Cancer. 21(1). 291–291.
7.
George, Tracy I., Karen Moser, Andreas Reiter, et al.. (2021). Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study. Blood. 138(Supplement 1). 2565–2565.
8.
Collins, Graham P., Rakesh Popat, Anastasios Stathis, et al.. (2016). A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma. Blood. 128(22). 5893–5893.
9.
Adjei, Alex A., Grace K. Dy, Yujie Zhao, et al.. (2016). A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). 2560–2560.
10.
Korfel, Agnieszka, Elisabeth Schorb, Uwe Schlegel, et al.. (2016). Targeting mTOR/PI3K in Primary CNS Lymphoma (PCNSL). Clinical Lymphoma Myeloma & Leukemia. 16. S107–S108.
11.
Jorga, Karin, et al.. (2016). Abstract 378: Exploring intermittent dosing schedules for the Pan PI3K/mTor inhibitor PQR309. Cancer Research. 76(14_Supplement). 378–378.
12.
Nogová, Lucia, Ronald Boellaard, Carsten Kobe, et al.. (2009). Downregulation of 18F-FDG Uptake in PET as an Early Pharmacodynamic Effect in Treatment of Non–Small Cell Lung Cancer with the mTOR Inhibitor Everolimus. Journal of Nuclear Medicine. 50(11). 1815–1819.
13.
Soria, Jean‐Charles, Frances A. Shepherd, Jean‐Yves Douillard, et al.. (2009). Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Annals of Oncology. 20(10). 1674–1681.
14.
Tabernero, Josep, Federico Rojo, Emiliano Calvo, et al.. (2008). Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 26(10). 1603–1610.
15.
Bono, Petri, Andreas Krause, Margaret von Mehren, et al.. (2004). Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 103(8). 2929–2935.
16.
Went, Philip, Stephan Dirnhofer, Marcel Bundi, et al.. (2004). Prevalence of KIT Expression in Human Tumors. Journal of Clinical Oncology. 22(22). 4514–4522.
17.
Judson, Ian, Peiming Ma, Bin Peng, et al.. (2004). Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemotherapy and Pharmacology. 55(4). 379–386.
18.
Heinrich, Michael C., Christopher L. Corless, George D. Demetri, et al.. (2003). Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 21(23). 4342–4349.
19.
Johnson, Bruce E., Thomas Fischer, B. Fischer, et al.. (2003). Phase II study of imatinib in patients with small cell lung cancer.. PubMed. 9(16 Pt 1). 5880–7.
20.
Oosterom, Allan T. van, Ian Judson, Jaap Verweij, et al.. (2002). Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer. 38. S83–S87.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sandra Silberman Breakdown of academic impact, for papers by Jonathan A. Fletcher Breakdown of academic impact, for papers by Maria Dêbiec‐Rychter Breakdown of academic impact, for papers by A. van Oosterom Breakdown of academic impact, for papers by Jonathan C. Trent Breakdown of academic impact, for papers by Annick D. Van den Abbeele Breakdown of academic impact, for papers by Laura McGreevey Breakdown of academic impact, for papers by Ajia Town Breakdown of academic impact, for papers by Maarit Sarlomo‐Rikala Breakdown of academic impact, for papers by Axel Le Cesne